153 related articles for article (PubMed ID: 11854548)
1. The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern?
Keefe DL
Oncologist; 2002; 7(1):65-72. PubMed ID: 11854548
[TBL] [Abstract][Full Text] [Related]
2. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists.
Navari RM; Koeller JM
Ann Pharmacother; 2003 Sep; 37(9):1276-86. PubMed ID: 12921512
[TBL] [Abstract][Full Text] [Related]
3. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
[TBL] [Abstract][Full Text] [Related]
4. Antiemetic agents.
Wilkes G
Oncology (Williston Park); 2007 Jul; 21(8 Suppl):48. PubMed ID: 17844897
[No Abstract] [Full Text] [Related]
5. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
[TBL] [Abstract][Full Text] [Related]
6. [Prevention and treatment of postoperative nausea and vomiting with 5-HT3-receptor blockers].
Alon E; Biro P
Anasthesiol Intensivmed Notfallmed Schmerzther; 1996 May; 31(4):200-4. PubMed ID: 8704077
[TBL] [Abstract][Full Text] [Related]
7. Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood.
Phillips RS; Gopaul S; Gibson F; Houghton E; Craig JV; Light K; Pizer B
Cochrane Database Syst Rev; 2010 Sep; (9):CD007786. PubMed ID: 20824866
[TBL] [Abstract][Full Text] [Related]
8. A phase I antiemetic study of MDL 73,147EF, a novel 5-hydroxytryptamine antagonist in cancer patients receiving emetogenic chemotherapy.
Merrouche Y; Catimel G; Rebattu P; Dumortier A; Guastalla JP; O'Grady P; Clavel M
Ann Oncol; 1994 Jul; 5(6):549-51. PubMed ID: 7918128
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of a continuous infusion, patient-controlled antiemetic pump for children receiving emetogenic chemotherapy.
Jones E; Koyama T; Ho RH; Kuttesch J; Shankar S; Whitlock JA; Cartwright J; Frangoul H
Pediatr Blood Cancer; 2007 Mar; 48(3):330-2. PubMed ID: 16304666
[TBL] [Abstract][Full Text] [Related]
10. Granisetron vs dolasetron for acute chemotherapy-induced nausea and vomiting (CINV) in high and moderately high emetogenic chemotherapy: an open-label pilot study.
Tan M; Xu R; Seth R
Curr Med Res Opin; 2004 Jun; 20(6):879-82. PubMed ID: 15200746
[TBL] [Abstract][Full Text] [Related]
11. Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists.
Babaoglu MO; Bayar B; Aynacioglu AS; Kerb R; Abali H; Celik I; Bozkurt A
Clin Pharmacol Ther; 2005 Dec; 78(6):619-26. PubMed ID: 16338277
[TBL] [Abstract][Full Text] [Related]
12. Is ondansetron more effective than granisetron for chemotherapy-induced nausea and vomiting? A review of comparative trials.
Vrabel M
Clin J Oncol Nurs; 2007 Dec; 11(6):809-13. PubMed ID: 18063539
[TBL] [Abstract][Full Text] [Related]
13. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy.
Audhuy B; Cappelaere P; Martin M; Cervantes A; Fabbro M; Rivière A; Khayat D; Bleiberg H; Faraldi M; Claverie N; Aranda E; Auclerc G; Audhuy B; Benhammouda A; Bleiberg H; Cals L; Cappelaere P; Cattan A; Cervantes A; Chevallier B; Conroy T; Cupissol D; De Grève J; Diaz-Rubio E; Seitz JF
Eur J Cancer; 1996 May; 32A(5):807-13. PubMed ID: 9081358
[TBL] [Abstract][Full Text] [Related]
14. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
Mantovani G; Macciò A; Bianchi A; Curreli L; Ghiani M; Proto E; Santona MC
Cancer; 1996 Mar; 77(5):941-8. PubMed ID: 8608488
[TBL] [Abstract][Full Text] [Related]
15. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.
Lofters WS; Pater JL; Zee B; Dempsey E; Walde D; Moquin JP; Wilson K; Hoskins P; Guevin RM; Verma S; Navari R; Krook JE; Hainsworth J; Palmer M; Chin C
J Clin Oncol; 1997 Aug; 15(8):2966-73. PubMed ID: 9256141
[TBL] [Abstract][Full Text] [Related]
16. [The antiemetic action of tropisetron (Navoban) in the cytostatic treatment of neoplastic diseases].
Buiuc AI; Găleşanu MR
Rev Med Chir Soc Med Nat Iasi; 1996; 100(3-4):160-4. PubMed ID: 9455457
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
Rapoport B; Schwartzberg L; Chasen M; Powers D; Arora S; Navari R; Schnadig I
Eur J Cancer; 2016 Apr; 57():23-30. PubMed ID: 26851398
[TBL] [Abstract][Full Text] [Related]
18. Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.
Herrstedt J
Expert Opin Drug Saf; 2004 May; 3(3):231-48. PubMed ID: 15155151
[TBL] [Abstract][Full Text] [Related]
19. Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009.
Jordan K; Roila F; Molassiotis A; Maranzano E; Clark-Snow RA; Feyer P;
Support Care Cancer; 2011 Mar; 19 Suppl 1():S37-42. PubMed ID: 20824481
[TBL] [Abstract][Full Text] [Related]
20. Comparison of tropisetron and granisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy.
Aksoylar S; Akman SA; Ozgenç F; Kansoy S
Pediatr Hematol Oncol; 2001 Sep; 18(6):397-406. PubMed ID: 11554235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
